The BET inhibitor Apabetalone protects against heart failure with preserved ejection fraction by suppressing myocardial inflammation

30 August 2024 (08:00 - 17:30)

Organised by:

Sign in for access options

Sign in to view the resources

Sign in for access options

About the speaker

Doctor Era Gorica

Center for Translational and Experimental Cardiology (CTEC), Zurich (Switzerland)

5 More presentations in this session

Presentation thumbnail

Targeting BRD4-HK2 reverses the meta-inflammatory shift in perivascular adipose tissue and rescues cardiometabolic vascular dysfunction.

Assistant Professor A. Mengozzi (Pisa, IT)

Abstract Slides Video

Presentation thumbnail

Targeting the histone methyltransferase SETD7 rescues diabetes-induced impairment of angiogenic response by transcriptional repression of semaphorin 3G

Doctor S. Mohammed (Zurich, CH)

Abstract Slides Video

Presentation thumbnail

Chromatin remodeling by the histone methyltransferase SETD2 drives cardiometabolic heart failure with preserved ejection fraction

Doctor S. Costantino (Zurich, CH)

Abstract Slides Video

Presentation thumbnail

Epigenetic BET inhibitor apabetalone counters inflammatory and fibrotic processes in activated cardiac fibroblasts providing insight into reduced hospitalizations for heart failure in BETonMACE trial

Doctor E. Kulikowski (Calgary, CA)

Abstract Slides Video

Presentation thumbnail

RBM20 promotes doxorubicin-induced cardiotoxicity by Atp6v0a1 alternative splicing

Doctor Z. Qiu (Shanghai, CN)

Abstract Slides Video

Access the full session

Session thumbnail

Epigenetic targets in cardiovascular disease

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024

You may be interested in

Congress Presentation

Basic science

Congress Presentation

European Heart Journal

Congress Presentation

ESC Textbook of Heart Failure

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources